Vivos Therapeutics (VVOS) Accounts Payables (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Accounts Payables data on file, last reported at $2.0 million in Q1 2026.

• Quarterly Accounts Payables rose 65.51% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (up 65.51% YoY) and the FY2025 annual result came in at $1.7 million, up 52.91% from the prior year.
• Accounts Payables improved to $2.0 million in Q1 2026 per VVOS's latest filing, from $1.7 million in the prior quarter.
• Across five years, Accounts Payables topped out at $2.5 million in Q1 2024 and bottomed at $644000.0 in Q3 2022.
• The 5-year median for Accounts Payables is $1.5 million (2023), against an average of $1.5 million.
• The widest annual swing landed in 2023, when Accounts Payables soared 137.27%; it then tumbled 51.74% in 2025.
• Tracing VVOS's Accounts Payables over 5 years: stood at $1.4 million in 2022, then soared by 52.02% to $2.1 million in 2023, then sank by 48.81% to $1.1 million in 2024, then soared by 52.91% to $1.7 million in 2025, then increased by 18.88% to $2.0 million in 2026.
• Per Business Quant, the three latest VVOS Accounts Payables figures stand at $2.0 million (Q1 2026), $1.7 million (Q4 2025), and $2.1 million (Q3 2025).

Peer Comparison